ICH Releases Additional Guidance on Combination Drug Toxicity Testing

Posted 12 January 2012 | By Alexander Gaffney, RAC 

The International Conference on Harmonization (ICH) released a new Question and Answer document on 11 January that provides additional guidance on ICH document M3(R2) - Combination Drug Toxicity Testing.

The new Q&A addresses a series of questions including:

  • how to conducting toxicity testing on combination products with different toxicity profiles
  • clarity regarding testing differences between the European medicines Agency and US Food and Drug Administration
  • determining the dosage, duration and endpoint of toxicity studies
  • testing non-fixed-dose combination products where one agent is a member of a class containing multiple approved products
  • determining "adequate clinical experience with co-administration" in late stage products
  • how to test multiple entity combinations when there is cause for concern
  • determining if pharmacology studies replace combination toxicity studies in certain cases
  • how to conduct toxicity testing for embryo-fetal development studies
  • how to develop therapies for life-threatening or serious diseases
  • how M3(R2) applies to biotechnology products

ICH M3(R2) is currently entering Step 5 which will further revise the guidance.

ICH documents are meant to bind the regulatory processes of the EU, US, and Japan.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Most Viewed Articles